Omeros Settles Infringement Suit Against Lupin Over Proposed Omidria Generic

June 1, 2018: By Jon Swedien

Legal issueSeattle-based Omeros announced May 24 that it has signed an agreement with India-based Lupin that resolves patent litigation over a proposed generic for Omeros’ Omidria.

Omeros sued Lupin after the Indian company’s US-based subsidiary, Lupin Pharmaceuticals, began pursuing an abbreviated new drug application with the US FDA for a generic version of Omidria.

Surgeons use Omidria (phenylephrine and ketorolac injection) during cataract surgery to maintain pupil size by preventing miosis and for reducing postoperative ocular pain.

In 2017, Omeros settled litigation over an abbreviated new drug application filing by Par Sterile Products and Par Pharmaceutical, Omeros said.

As with the Par settlement, Lupin acknowledged and confirmed the validity of all Omeros’ Omidria patents, Omeros said. Omeros did not disclose if there were any payments included in the deal.

Omidria’s patent protection expires Oct. 23, 2033.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT